secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-09-15T12:31:45+00:00
Accession:  0001628280-26-061973
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin discontinues VOXZOGO development for Noonan syndrome
-------------------------------------------------------------

- Decision announced Sept 15, 2026; development halted for Noonan syndrome indication.
- Cites study feasibility and current treatment landscape as reasons.
- Company states decision not related to safety or efficacy of VOXZOGO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/0001628280-26-061973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/bmrn-20260915.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-061973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer